Group 1 - The core point of the news is that Guangdong Taiankang Pharmaceutical Co., Ltd. has disclosed its employee stock ownership plan for 2026, aiming to raise a maximum of 33.608 million yuan, with participation from up to 145 individuals including directors, senior management, and key employees [1] - The employee stock ownership plan is closely tied to the company's performance over the next three years, with assessment indicators including both "operating revenue" and "assessed profit," targeting significant growth [1][2] - The plan outlines specific unlock periods and performance targets, with the first unlock period set for 2026, requiring operating revenue to reach 1 billion yuan and assessed profit to hit 270 million yuan [2] Group 2 - The company is expected to see significant revenue growth as several core products are set to be approved or submitted for approval, including a domestic first generic of lidocaine and prilocaine aerosol, which is anticipated to complete registration by 2026 [2][3] - Participants in the employee stock ownership plan are required to use their own funds for subscription, with shares sourced from the company's repurchased stock at a price of 16.93 yuan per share [3] - The company believes that this long-term mechanism of employee stock ownership will effectively motivate the core team's enthusiasm and creativity, promoting the research, market promotion, and sales of core products to ensure the achievement of high growth targets [3]
泰恩康发布2026年员工持股计划 彰显公司发展信心